The FDA on June 17, 2024, approved KEYTRUDA® with Carboplatin and Paclitaxel, followed by single-agent KEYTRUDA®, for adult patients with primary advanced or recurrent Endometrial carcinoma. KEYTRUDA® is a product of Merck & Co., Inc.
Bottom Ad
Advertisement
Subscribe
